Study of NM8074 for adults with C3 glomerulopathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new medicine called NM8074 for adults with C3 glomerulopathy, a kidney disease. The medicine may help reduce kidney damage. Participants will receive the study drug and be monitored for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with C3 glomerulopathy, confirmed by a kidney biopsy within the last 12 months.
- Your blood tests show low levels of a protein called C3.
- You have protein in your urine.
- Your kidney function (measured by eGFR) is between 20 and 60 mL/min.
- You are willing to get vaccinated against certain bacteria before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
This trial tests whether aliskiren works better or as well as enalapril to treat C3 glomerulopathy/dense deposit disease confirmed by a kidney biopsy. It may help by improving kidney outcomes in people with this specific kidney condition.
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
This study follows people in Russia with C3 glomerulopathy or IC-MPGN to understand how these kidney diseases progress over time. It does not test a new treatment, but gathers information from medical records and check-ups to learn more about the conditions.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.